quinazolines has been researched along with Granulocytic Leukemia, Chronic in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (11.11) | 18.2507 |
| 2000's | 17 (47.22) | 29.6817 |
| 2010's | 13 (36.11) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, B; Du, X; Gong, Z; Ji, Y; Li, S; Ma, W; Shi, X; Wang, B; Wang, Y; Yang, T; Zhan, Y; Zhang, D; Zhang, Y; Zhu, M | 1 |
| Jin, Y; Lai, P; Li, S; Liu, C; Nie, D; Zhang, X; Zhou, M | 1 |
| Usui, N | 1 |
| Azimi, A; Badalzadeh, R; Baradaran, B; Majidinia, M; Samadi, N; Shafiei-Irannejad, V; Yousefi, B; Zarghami, N | 1 |
| Lambrecht, AM; Larocque, EA; Naganna, N; Opoku-Temeng, C; Sintim, HO | 1 |
| Almeida, VH; Berzoti-Coelho, MG; Borges, CS; Cacemiro, MDC; Castro, FA; Ferreira, AF; Figueiredo-Pontes, LL; Gomes, FG; Monteiro, RQ; Nunes, NS; Simões, BP | 1 |
| Baksiene, S; Borutinskaite, V; Navakauskiene, R; Vitkeviciene, A | 1 |
| Al-Dhfyan, A; Alanazi, FK; Radwan, AA | 1 |
| Cortelazzo, S; Corvetta, D; Gastl, G; Mazzoleni, G; Piccin, A; Pusceddu, I; Rovigatti, U; Steurer, M; Svaldi, M | 1 |
| Bai, H; Li, S; Qin, Y; Shao, S; Wang, C; Wang, X; Yang, Y; Zhao, C; Zhou, L | 1 |
| Ea, CK; Lim, YY; Loh, SW; Ng, WL; Yeo, KS | 1 |
| Ohyashiki, K; Okabe, S; Sakuta, J; Tanaka, Y; Tauchi, T | 1 |
| Bacic, B; Gwanmesia, PM; Ottmann, OG; Romanski, A; Ruthardt, M; Schwarz, K | 1 |
| Dorans, K | 1 |
| Baba, N; Fujio, K; Kimura, S; Kohno, M; Kosugi, M; Ozaki, K; Sakamoto, T; Tanimura, S | 1 |
| Hua, W; Miao, Q; Miao, S; Shi, X; Sun, J; Wang, S; Zhang, C; Zhang, H; Zhao, Y | 1 |
| Botta, M; Brullo, C; Musumeci, F; Schenone, S | 1 |
| Brink, DJ; Mazer, MA; Raghavan, M | 1 |
| Benowitz, S | 1 |
| Fruchtman, SM | 1 |
| Silver, RT | 1 |
| Christoffersen, T; Dajani, O; Guren, TK; Thoresen, GH; Tveit, KM; Wisløff, F | 1 |
| Cabello, P; Cesar, JM; Ferro, T; Navarro, JL | 1 |
| Levitzki, A; Mishani, E | 1 |
| Beránek, M; Chrobák, L; Maisnar, V; Voglová, J | 1 |
| Hampton, T | 1 |
| Bennett, M; Chubar, E | 1 |
| Barutca, S; Bolaman, Z; Kadikoylu, G; Meydan, N; Yavasoglu, I | 1 |
| Fojo, T | 1 |
| Gibson, W; Jackman, AL; Kimbell, R; Kobayashi, H; Miyachi, H; Takemura, Y | 1 |
| Kobayashi, H; Ohnuma, T; Takemura, Y | 1 |
| Beykirch, MK; Petrides, PE; Trapp, OM | 1 |
| Lindemann, A; Mertelsmann, R; Schoepf, E; Wirth, K | 1 |
| Pavithran, K; Somarajan, A; Thomas, M | 1 |
| Bennett, M; Grunwald, AJ | 1 |
| Eftyhiadis, E; Komninaka, V; Loukopoulos, D; Mantzourani, M; Terpos, E; Voskaridou, E | 1 |
5 review(s) available for quinazolines and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
An update on dual Src/Abl inhibitors.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzodioxoles; Dasatinib; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; Quinolines; src-Family Kinases; Thiazoles | 2012 |
Treatment paradigms in the management of myeloproliferative disorders.
Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Myeloproliferative Disorders; Philadelphia Chromosome; Platelet Aggregation Inhibitors; Quinazolines; Radiopharmaceuticals | 2004 |
[Antineoplastic agents targeting tyrosine kinases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Trastuzumab | 2005 |
Tyrphostins and other tyrosine kinase inhibitors.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Graft Occlusion, Vascular; Humans; Imatinib Mesylate; Janus Kinase 2; Janus Kinase 3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tyrphostins | 2006 |
Commentary: Novel therapies for cancer: why dirty might be better.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubules; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Purinergic P2 | 2008 |
2 trial(s) available for quinazolines and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia.
Topics: Adult; Drug Resistance; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Quinazolines; Thrombocytosis | 2005 |
Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count.
Topics: Aged; Female; Hematologic Tests; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines | 1998 |
29 other study(ies) available for quinazolines and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4.
Topics: Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Ephrins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Piperidines; Quinazolines | 2022 |
Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Primary Cell Culture; Quinazolines; SOXD Transcription Factors; Xenograft Model Antitumor Assays | 2021 |
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN).
Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imidazoles; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Nitriles; Phlebotomy; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; Quinolines; Risk | 2017 |
Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPARγ-dependent manner in leukemia cells.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polymerase Chain Reaction; PPAR gamma; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Thiazolidinediones; Up-Regulation | 2017 |
Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase.
Topics: Alkynes; Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Imatinib Mesylate; Imidazoles; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Docking Simulation; Naphthyridines; Niacinamide; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyridazines; Quinazolines | 2018 |
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Chromones; Disease Progression; Dose-Response Relationship, Drug; Female; Flavonoids; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Myeloid Cells; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptor, PAR-1; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2018 |
Epigallocatechin-3-gallate and BIX-01294 have different impact on epigenetics and senescence modulation in acute and chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Azepines; Catechin; Cellular Senescence; Chromobox Protein Homolog 5; Drug Screening Assays, Antitumor; Epigenesis, Genetic; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Quinazolines | 2018 |
Synthesis, and docking studies of some fused-quinazolines and quinazolines carrying biological active isatin moiety as cell-cycle inhibitors of breast cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Humans; Inhibitory Concentration 50; Isatin; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Quinazolines; Structure-Activity Relationship | 2013 |
Essential thrombocytemia progressing to Ph+ chronic myeloid leukemia with megakaryoblastic blasts, following anagrelide withdrawal.
Topics: Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocyte Progenitor Cells; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential | 2014 |
Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Benzamides; Benzylamines; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Pyrimidines; Quinazolines | 2014 |
Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment.
Topics: Antineoplastic Agents; Apoptosis; Azepines; Benzamides; Cell Proliferation; Drug Synergism; Gene Expression; HeLa Cells; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Imatinib Mesylate; Interferon Type I; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Quinazolines | 2014 |
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasms, Experimental; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines | 2016 |
The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzodioxoles; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; src-Family Kinases | 2009 |
Outpacing cancer.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines | 2009 |
Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
Topics: Analgesics; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines | 2010 |
Proliferation-attenuating and apoptosis-inducing effects of tryptanthrin on human chronic myeloid leukemia K562 cell line in vitro.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Proliferation; Cytochromes c; DNA Fragmentation; Enzyme Activation; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2011 |
Severe hypersensitivity pneumonitis associated with anagrelide.
Topics: Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Drug Interactions; Female; Humans; Hydroxyurea; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 2003 |
As targeted therapies evolve, challenges remain.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Drug Screening Assays, Antitumor; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Quinazolines | 2004 |
Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
Topics: Aged; Antineoplastic Agents; Benzamides; Blood Platelets; Bone Marrow Cells; Cells, Cultured; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Chronic Disease; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Piperazines; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic; Treatment Outcome | 2006 |
[Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thrombocytosis | 2006 |
New blood cancer therapies under study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Aurora Kinases; ErbB Receptors; Erlotinib Hydrochloride; Hematologic Neoplasms; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Rituximab | 2007 |
Chronic myeloid leukemia evolving after idiopathic myelofibrosis.
Topics: Adult; Blood Cell Count; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Megakaryocytes; Primary Myelofibrosis; Quinazolines; Splenomegaly; Thrombocytopenia; Translocation, Genetic | 2007 |
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Leucovorin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Philadelphia Chromosome; Quinazolines; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thiophenes | 2008 |
Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.
Topics: Antimetabolites, Antineoplastic; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Folic Acid; Humans; Intracellular Fluid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polyglutamic Acid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinazolines; Tetrahydrofolate Dehydrogenase; Thiophenes; Thymidylate Synthase; Tritium; Tumor Cells, Cultured | 1996 |
Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Carrier Proteins; Drug Resistance, Neoplasm; Folic Acid; Folic Acid Antagonists; Humans; Leucovorin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Membrane Transport Proteins; Methotrexate; Phenotype; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quinazolines; Tetrahydrofolate Dehydrogenase; Thiophenes; Tumor Cells, Cultured | 1998 |
Leg ulceration with associated thrombocytosis: healing of ulceration associated with treatment of the raised platelet count.
Topics: Female; Humans; Leg Ulcer; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Paraneoplastic Syndromes; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis | 1998 |
Thrombocytosis--report of a case.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis | 2000 |
Hydroxyurea and periodicity in myeloproliferative disease.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Busulfan; Female; Hemoglobins; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Periodicity; Platelet Count; Polycythemia Vera; Quinazolines | 2001 |
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Topics: Adult; Antisickling Agents; beta-Thalassemia; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Remission Induction; Thrombocytosis | 2002 |